Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 2/20 | 0.60 |
| ▸ | CYP46A1 | Q9Y6A2 | 2/20 | 0.60 |
| ▸ | LMNA | P02545 | 1/20 | 0.60 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.60 |
| ▸ | OSBP | P22059 | 1/20 | 0.60 |
| ▸ | RORC | P51449 | 1/20 | 0.60 |
| ▸ | OSBP2 | Q969R2 | 1/20 | 0.60 |
| ▸ | POLA1 | P09884 | 1/20 | 0.57 |
| ▸ | GRIN1 | Q05586 | 12/20 | 0.56 |
| ▸ | GRIN2B | Q13224 | 12/20 | 0.56 |
| ▸ | GRIN2A | Q12879 | 10/20 | 0.55 |
| ▸ | SRD5A1 | P18405 | 2/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL998341 | 0.92 | USP2 (0.60) | USP2CYP46A1LMNAABCB1OSBP | |
| SCHEMBL19692309 | 0.92 | USP2 (0.60) | USP2CYP46A1LMNAABCB1OSBP | |
| SCHEMBL19691912 | 0.92 | USP2 (0.60) | USP2CYP46A1LMNAABCB1OSBP | |
| SCHEMBL1050027 | 0.91 | USP2 (0.59) | USP2CYP46A1LMNAABCB1OSBP | |
| SCHEMBL1081197 | 0.91 | USP2 (0.59) | USP2CYP46A1LMNAABCB1OSBP | |
| SCHEMBL22658123 | 0.91 | USP2 (0.59) | USP2CYP46A1LMNAABCB1OSBP | |
| SCHEMBL8205164 | 0.91 | USP2 (0.59) | USP2CYP46A1LMNAABCB1OSBP | |
| SCHEMBL2440566 | 0.91 | OSBP (0.58) | USP2CYP46A1LMNAABCB1OSBP | |
| Hydrochloric Acid SCHEMBL11907786 | 0.91 | USP2 (0.58) | USP2CYP46A1LMNAABCB1OSBP | |
| SCHEMBL18797660 | 0.91 | USP2 (0.58) | USP2CYP46A1LMNAABCB1OSBP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117843982-A | Highly branched poly (beta-amino ester) containing cholesterol and phosphoric acid modification, synthesis method thereof and mRNA delivery application | 西安交通大学 | 2024-04-09 | — | — | CN | claimed |
| CN-117843982-A | Highly branched poly (beta-amino ester) containing cholesterol and phosphoric acid modification, synthesis method thereof and mRNA delivery application | 西安交通大学 | 2024-04-09 | — | — | CN | disclosed |
| CN-101686940-B | Method for delivering protein into cell | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2014-10-22 | — | — | CN | disclosed |
| US-8821859-B2 | Methods and articles for the delivery of therapeutic agents | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2014-09-02 | — | — | US | disclosed |
| US-8425900-B2 | Method of delivering a protein into a cell | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2013-04-23 | — | — | US | disclosed |
| CN-102895668-A | Method of delivering a protein into a cell | AGENCY SCIENCE TECH & RES | 2013-01-30 | — | — | CN | disclosed |
| US-20100119501-A1 | METHOD OF DELIVERING A PROTEIN INTO A CELL | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2010-05-13 | — | — | US | disclosed |
| CN-101686940-A | Method for delivering protein into cell | AGENCY SCIENCE TECH & RES | 2010-03-31 | — | — | CN | disclosed |
| EP-1750666-A2 | METHODS AND ARTICLES FOR THE DELIVERY OF THERAPEUTIC AGENTS | Agency for Science, Technology and Research (SG) | 2007-02-14 | — | — | EP | disclosed |
| WO-2005112886-A2 | METHODS AND ARTICLES FOR THE DELIVERY OF THERAPEUTIC AGENTS | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2005-12-01 | — | — | WO | disclosed |
| US-20050260276-A1 | Methods and articles for the delivery of therapeutic agents | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2005-11-24 | — | — | US | disclosed |
| EP-1572029-A1 | METHOD OF LOADING BENEFICIAL AGENT TO A PROSTHESIS BY FLUID-JET APPLICATION | Abbott Laboratories (US) | 2005-09-14 | — | — | EP | disclosed |
| WO-2004043299-A1 | METHOD OF LOADING BENEFICIAL AGENT TO A PROSTHESIS BY FLUID-JET APPLICATION | ABBOTT LABORATORIES (US) | 2004-05-27 | — | — | WO | disclosed |
| WO-2003094971-A1 | CATIONIC LIPIDS FOR INTRACELLULAR DELIVERY OF BIOACTIVE SUBSTANCES | JOHNS HOPKINS SINGAPORE PTE LTD (SG) | 2003-11-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050260276-A1 | Methods and articles for the delivery of therapeutic agents | MTREX, SNRPA, ANXA6 | USP2 1573/4885CYP46A1 4170/4885LMNA 154/4885 |
| US-20100119501-A1 | METHOD OF DELIVERING A PROTEIN INTO A CELL | LNPEP, ANXA6, PPHLN1 | USP2 1054/4885CYP46A1 3487/4885LMNA 1233/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.